Inactive Instrument

All News Oasmia Pharmaceutical AB NORDIC GROWTH MARKET

Equities

OASM

SE0000722365

All News

Unlock all the news: Be the first to know and act before the market!

Vivesto receives positive Cantrixil preclinical efficacy data	Jul. 01	AQ
Vivesto AB Receives Positive Cantrixil Preclinical Efficacy Data	Jul. 01	CI
Report from Annual General Meeting in Vivesto AB	May. 23	AQ
Vivesto AB Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 23	CI
Notice of Annual General Meeting in Vivesto AB	Apr. 23	AQ
Transcript : Vivesto AB - Special Call	Mar. 26
Vivesto to hold live-streamed Paccal Vet R&D Update on March 26	Mar. 19	AQ
Vivesto doses first patient in its clinical Paccal Vet trial	Mar. 07	AQ
Vivesto AB Doses First Patient in its Clinical Paccal Vet Trial	Mar. 07	CI
Vivesto AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Vivesto's international patent application for XR-18 receives positive decision	Jan. 30	AQ
Vivesto's International Patent Application for XR-18 Receives Positive Decision	Jan. 30	CI
Vivesto Gains on Receipt of US Approval for Pilot Clinical Trial of Drug Candidate Paccal Vet	Dec. 28	MT
Vivesto’s US clinical Paccal Vet trial receives approval to start patient recruitment	Dec. 28	AQ
Vivesto AB's US Clinical Paccal Vet Trial Receives Approval to Start Patient Recruitment	Dec. 28	CI
Vivesto’s Paccal Vet granted FDA MUMS designation	Dec. 22	AQ
Vivesto makes impairment charge following withdrawal of European market authorizations for Apealea	Dec. 22	AQ
Vivesto AB Reports Positive Preclinical Data Supporting Continued Development of Cantrixil	Dec. 19	CI
Vivesto reports positive preclinical data supporting continued development of Cantrixil	Dec. 19	AQ
Nomination Committee appointed for the 2024 Annual General Meeting in Vivesto	Nov. 23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Oasmia Pharmaceutical AB NORDIC GROWTH MARKET

Equities

OASM

SE0000722365

All News

Filters